Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Qin Ying Lim"'
Autor:
Nick Ka Ming Yau, Ian C. K. Wong, Qin Ying Lim, Vivian Wai Yan Lui, Krista Roberta Verhoeft, WY Lam, Andrew Yuon Fong, Hiu Fung Leung
Publikováno v:
Current Cancer Drug Targets. 15:327-336
The anaplastic lymphoma kinase (ALK) is a druggable target for cancer therapy. By and large, the oncogenic activation of ALK in human tumors is known to occur by gene rearrangement (e.g. EML4-ALK, NMP-ALK, etc.). Clinical use of ALK inhibitors for "A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f774a8ebf25865e3f7907bc1404b68b7
https://doi.org/10.2174/1568009615666150225123712
https://doi.org/10.2174/1568009615666150225123712
Autor:
Nick Ka Ming, Yau, Andrew Yuon, Fong, Hiu Fung, Leung, Krista Roberta, Verhoeft, Qin Ying, Lim, Wai Yip, Lam, Ian Chi Kei, Wong, Vivian Wai Yan, Lui
Publikováno v:
Current cancer drug targets. 15(4)
The anaplastic lymphoma kinase (ALK) is a druggable target for cancer therapy. By and large, the oncogenic activation of ALK in human tumors is known to occur by gene rearrangement (e.g. EML4-ALK, NMP-ALK, etc.). Clinical use of ALK inhibitors for "A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d57f1ff37f98d4f2c1b3633d6977e7c9
https://pubmed.ncbi.nlm.nih.gov/25714698
https://pubmed.ncbi.nlm.nih.gov/25714698